PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

詳細記述

保存先:
書誌詳細
出版年:Medicine (Baltimore)
主要な著者: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
フォーマット: Artigo
言語:Inglês
出版事項: Wolters Kluwer Health 2014
主題:
4200
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://ncbi.nlm.nih.gov/pubmed/25526490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000326
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料